CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTMX POWR Grades
- Value is the dimension where CTMX ranks best; there it ranks ahead of 69.06% of US stocks.
- CTMX's strongest trending metric is Momentum; it's been moving down over the last 157 days.
- CTMX ranks lowest in Momentum; there it ranks in the 4th percentile.
CTMX Stock Summary
- Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 13.49% of US stocks have a lower such ratio.
- As for revenue growth, note that CTMX's revenue has grown -28.23% over the past 12 months; that beats the revenue growth of merely 7.1% of US companies in our set.
- CytomX Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -47.55%, greater than the shareholder yield of only 8.44% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to CytomX Therapeutics Inc, a group of peers worth examining would be PLRX, AGLE, JNCE, MEIP, and GLYC.
- Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to www.cytomx.com.
CTMX Valuation Summary
- In comparison to the median Healthcare stock, CTMX's price/earnings ratio is 114.25% lower, now standing at -5.2.
- CTMX's price/sales ratio has moved down 56.3 over the prior 72 months.
- Over the past 72 months, CTMX's EV/EBIT ratio has gone up 14.3.
Below are key valuation metrics over time for CTMX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CTMX | 2021-08-31 | 5.0 | 2.5 | -5.2 | -1.5 |
| CTMX | 2021-08-30 | 5.0 | 2.5 | -5.1 | -1.5 |
| CTMX | 2021-08-27 | 5.1 | 2.6 | -5.3 | -1.6 |
| CTMX | 2021-08-26 | 5.0 | 2.5 | -5.1 | -1.4 |
| CTMX | 2021-08-25 | 4.9 | 2.5 | -5.1 | -1.4 |
| CTMX | 2021-08-24 | 4.9 | 2.5 | -5.1 | -1.4 |
CTMX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CTMX has a Quality Grade of D, ranking ahead of 22.16% of graded US stocks.
- CTMX's asset turnover comes in at 0.169 -- ranking 210th of 682 Pharmaceutical Products stocks.
- JNJ, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.
The table below shows CTMX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.169 | 1 | -0.872 |
| 2021-03-31 | 0.170 | 1 | -0.944 |
| 2020-12-31 | 0.255 | 1 | -0.424 |
| 2020-09-30 | 0.237 | 1 | -0.610 |
| 2020-06-30 | 0.219 | 1 | -0.636 |
| 2020-03-31 | 0.200 | 1 | -0.554 |
CTMX Price Target
For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
CTMX Stock Price Chart Interactive Chart >
CTMX Price/Volume Stats
| Current price | $3.83 | 52-week high | $10.05 |
| Prev. close | $3.95 | 52-week low | $3.67 |
| Day low | $3.83 | Volume | 1,170,206 |
| Day high | $4.28 | Avg. volume | 807,045 |
| 50-day MA | $5.73 | Dividend yield | N/A |
| 200-day MA | $6.18 | Market Cap | 249.90M |
CytomX Therapeutics, Inc. (CTMX) Company Bio
CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.
Latest CTMX News From Around the Web
Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.
10 Small-Cap Stocks to Buy According to Billionaire Steve CohenIn this article, we discuss the 10 small-cap stocks to buy according to billionaire Steve Cohen. You can skip our detailed analysis of Steve Cohen’s hedge fund, and go directly to read 5 Small-Cap Stocks to Buy According to Billionaire Steve Cohen. Billionaire investor Steve Cohen is the brain behind Point72 Asset Management, a hedge fund […] |
CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www. |
Is CytomX Stock a Buy Following Disappointing Cancer Therapy Results? Analyst Weighs InAn investment in a biotech company is not without risk, and last week, CytomX Therapeutics (CTMX) investors got a painful reminder of the consequences should clinical testing not go as hoped for. Shares dropped by 40% in a single session after the data from the Phase 2 trial of experimental cancer therapy CX-2029 failed to impress. The study was assessing the drug as a treatment for patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell carcinoma (HNSCC). For the former group, the data showed an objective response rate (ORR) of 18.8% and a disease-control rate (DCR) of 87. |
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and CytomX Therapeutics (CTMX)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Esperion (ESPR – Research Report) and CytomX Therapeutics (CTMX – Research Report). Esperion (ESPR) J.P. Morgan analyst Jessica Fye maintained a Sell rating on Esperion yesterday and set a price target of $6.00. The company's shares closed last Wednesday at $5.15, close to its 52-week low of $4.85. According to TipRanks. |
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Chimerix (CMRX) and CytomX Therapeutics (CTMX)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND – Research Report), Chimerix (CMRX – Research Report) and CytomX Therapeutics (CTMX – Research Report) with bullish sentiments. Ligand Pharma (LGND) H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma today and set a price target of $310.00. The company's shares closed last Tuesday at $151.02. According to TipRanks. |
CTMX Price Returns
| 1-mo | -40.06% |
| 3-mo | -24.46% |
| 6-mo | -31.97% |
| 1-year | N/A |
| 3-year | -77.15% |
| 5-year | -66.70% |
| YTD | -11.55% |
| 2021 | -33.89% |
| 2020 | -21.18% |
| 2019 | -44.97% |
| 2018 | -28.47% |
| 2017 | 92.08% |
Continue Researching CTMX
Want to do more research on CytomX Therapeutics Inc's stock and its price? Try the links below:CytomX Therapeutics Inc (CTMX) Stock Price | Nasdaq
CytomX Therapeutics Inc (CTMX) Stock Quote, History and News - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...